Evidence map›Paper›PMID 30206777›Full record

ArticleClinical journal of gastroenterology2019

A case of gastric cancer with delayed onset of tumor reduction effect by nivolumab therapy.

Rika Satoyoshi, Osamu Muto, Akio Masuda, Kei Kotanagi, Takuya Kichiraku, Kazuhiro Kudoh, Toshiya Sawada, Hideaki Miyazawa, Hitoshi Kotanagi

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Clinical journal of gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Rika SatoyoshiDepartment of Gastroenterological Surgery, Akita Red Cross Hospital, Akita, Japan. rika_satoyoshi@akita-med.jrc.or.jp.
Osamu MutoDepartment of Medical Oncology, Akita Red Cross Hospital, Akita, Japan.
Akio MasudaDepartment of Gastroenterological Surgery, Akita Red Cross Hospital, Akita, Japan.
Kei KotanagiDepartment of Gastroenterological Surgery, Akita Red Cross Hospital, Akita, Japan.
Takuya KichirakuDepartment of Gastroenterological Surgery, Akita Red Cross Hospital, Akita, Japan.
Kazuhiro KudohDepartment of Gastroenterological Surgery, Akita Red Cross Hospital, Akita, Japan.
Toshiya SawadaDepartment of Gastroenterological Surgery, Akita Red Cross Hospital, Akita, Japan.
Hideaki MiyazawaDepartment of Gastroenterological Surgery, Akita Red Cross Hospital, Akita, Japan.
Hitoshi KotanagiDepartment of Gastroenterological Surgery, Akita Red Cross Hospital, Akita, Japan.
Akita Red Cross Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors may have different clinical effects compared with conventional anticancer drugs. An 85-year-old male received chemotherapy for recurrent gastric cancer. As liver metastasis progressed, nivolumab was introduced as a fourth line treatment. Progression of liver metastasis in size was observed in CT after 3 courses of nivolumab therapy. Nivolumab treatment was discontinued, because the general condition of the patient also worsened. However, his general condition improved as hepatobiliary enzyme levels, inflammatory response, and tumor markers improved. Liver metastasis was shrinking on the image, so we resumed nivolumab therapy. To the authors' knowledge, this is the first case of pseudoprogression undergoing immunotherapy for gastric cancer. In this case, the antitumor effect was exhibited in a delayed manner and the tumor shrinkage was obtained.

Indexed as

AdenocarcinomaAged, 80 and overAntineoplastic Agents, ImmunologicalDisease ProgressionHumansLiver NeoplasmsMaleNeoplasm Recurrence, LocalNivolumabStomach NeoplasmsTime FactorsTomography, X-Ray ComputedTreatment OutcomeAntineoplastic Agents, ImmunologicalNivolumabGastric cancerMSINivolumabPseudoprogression

Identifiers

PMID30206777
OpenAlexW2890064792

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.